Adaptive mutability of colorectal cancers in response to targeted therapies
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
A cross-kingdom tale of drug resistance: Physicians who treat bacterial infections and those who treat cancer often face a common challenge: the development of drug resistance. It is well known that when bacteria are exposed to antibiotics, they temporarily increase their mutation rate, thus increasing the chance that a descendant antibiotic-resistant cell will arise. Russo et al. now provide evidence that cancer cells exploit a similar mechanism to ensure their survival after drug exposure (see the Perspective by Gerlinger). They found that human colorectal cancer cells treated with certain targeted therapies display a transient up-regulation of errorprone DNA polymerases and a reduction in their ability to repair DNA damage. Thus, like bacteria, cancer cells can adapt to therapeutic pressure by enhancing their mutability. Science , this issue p. 1473 ; see also p. 1458
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This observation may be due to a more potent treatment effect with the combination of divarasib and cetuximab imposing a stronger selective pressure and/or potentially increasing the adaptive mutability of the residual cancer cells30.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [30]
Citations
Cites
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
GENCODE: The reference human genome annotation for The ENCODE Project
Harrow, J., Frankish, A., Gonzalez, J. M., Tapanari, E., Diekhans, M., Kokocinski, F., Aken, B. L., Barrell, D., Zadissa, A., Searle, S., et al. (2012) · Genome Research · doi:10.1101/gr.135350.111 · Cited by 4,585
Mutations of bacteria from virus sensitivity to virus resistance
Luria, S. E., & Delbrück, M. (1943) · Genetics · doi:10.1093/genetics/28.6.491 · Cited by 3,894
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Self-citationEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
Self-citationThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
γH2AX: a sensitive molecular marker of DNA damage and repair
Mah, L.-J., El-Osta, A., & Karagiannis, T. C. (2010) · Leukemia · doi:10.1038/leu.2010.6 · Cited by 1,557
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491
Cited by
Items 101–200 of 435
Cheng, X., Zhao, F., Ke, B., Chen, D., & Liu, F. (2023) · Cancers · doi:10.3390/cancers15215209 · Cited by 44
“Moreover, abnormalities in DNA repair pathways like mismatch repair (MMR) and homologous recombination (HR) can lead to genomic instability and resistance to DNA-damaging agents [34–36].”
BackgroundAdaptive Evolution: How Bacteria and Cancer Cells Survive Stressful Conditions and Drug Treatment
Russo, M., Sogari, A., & Bardelli, A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1588 · Cited by 51
“Treatment with the anti-EGFR monoclonal antibody cetuximab, alone or in combination with the BRAF inhibitor dabrafenib, induced transient deficiency of both MMR and HR-mediated DNA-repair proficiency, and a concomitant switch from a high-to a low-fidelity DNA replication (38).”
InfluentialSelf-citationLu, H., Zhang, H., Weng, M., Zhang, J., Jiang, N., Cata, J. P., Ma, D., Chen, W., & Miao, C. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30161 · Cited by 40
“Most patients who are initially sensitive to anti‐EGFR therapy will eventually develop drug resistance approximately 15 months after treatment (Russo et al., 2019).”
BackgroundMaiorano, D., Etri, J. E., Franchet, C., & Hoffmann, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083924 · Cited by 46
“Furthermore, pharmacological inhibition of a Polζ–Rev1 complex improves melanoma chemotherapy [86], and a very recent report has interestingly shown that TLS Pols are upregulated in colorectal cancer resistant to BRAF and EGFR inhibitors, showing that TLS is a pathway that cells can activate to resist targeted therapy…”
BackgroundThe therapeutic and prognostic implications of immunobiology in colorectal cancer: a review
Zaborowski, A. M., Winter, D. C., & Lynch, L. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01475-x · Cited by 46
“EGFR/BRAF inhibition has been shown to downregulate MMR proteins in human colorectal tumours, triggering microsatellite instability and increasing mutagenesis [57].”
BackgroundImpact of cancer evolution on immune surveillance and checkpoint inhibitor response
Wu, Y., Biswas, D., & Swanton, C. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.013 · Cited by 46
“of DNA repair machinery, potentially driving resistance [55].”
BackgroundTherapy sculpts the complex interplay between cancer and the immune system during tumour evolution
Thol, K., Pawlik, P., & McGranahan, N. (2022) · Genome Medicine · doi:10.1186/s13073-022-01138-3 · Cited by 48
“by Cisplatin [51]); Stress-induced accelerated evolution [53, 54] Immunosuppression (platinum adducts cause apoptosis of lymphocytes [47–49]); Stress-induced accelerated evolution [53, 54]”
BackgroundCiracì, P., Studiale, V., Taravella, A., Antoniotti, C., & Cremolini, C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00965-0 · Cited by 53
“…ICIs are also currently under investigation and seem biologically plausible given preclinical data suggest that treatment of pMMR or MSS and BRAF V600E -mutant CRC with BRAF and EGFR inhibitors generates a switch towards a dMMR or MSI-H phenotype favouring the antitumour activity of ICIs 180–183 .”
Evolving insights: how DNA repair pathways impact cancer evolution
Zhou, J., Zhou, X. A., Zhang, N., & Wang, J. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0177 · Cited by 45
Zhang, L., Chen, J., He, M., & Su, X. (2022) · Exploration · doi:10.1002/exp.20210265 · Cited by 42
Raghav, K. P. S., Ou, F., Venook, A. P., Innocenti, F., Sun, R., Lenz, H., & Kopetz, S. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00365 · Cited by 42
“Epigenetic or transcriptional reprogramming and ensuing therapy-induced senescence or EMT (epithelial-to-mesenchymal transition) may enable mCRC to survive the brunt of combined targeted chemotherapy.(13,14) EMT gene expression signatures have been associated with both a generic resistance to cytotoxic chemotherapy an…”
BackgroundThe Mutagenic Impact of Environmental Exposures in Human Cells and Cancer: Imprints Through Time
Huber, A. R., van Hoeck, A., & van Boxtel, R. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.760039 · Cited by 43
“, 2015; Hawkins and Miles, 2021) or altered expression of DNA replication and repair enzymes, elevating mutational loads (Russo et al., 2019; Cipponi et al., 2020).”
BackgroundLiquid Biopsy in Colorectal Carcinoma: Clinical Applications and Challenges
Kolenčík, D., Shishido, S. N., Pitule, P., Mason, J. M., Hicks, J. B., & Kühn, P. (2020) · Cancers · doi:10.3390/cancers12061376 · Cited by 46
Cell-Intrinsic Mechanisms of Drug Tolerance to Systemic Therapies in Cancer
Léonce, C., Saintigny, P., & Ortiz‐Cuaran, S. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0038 · Cited by 44
“The authors suggested that the transient phenotype of DTP allows to establish the optimal mutational landscape to survive to treatment and to recover proliferative activity (63).”
BackgroundInfluentialLv, G., Wang, Q., Lin, L., Ye, Q., Li, X., Zhou, Q., Kong, X., Deng, H., You, F., Chen, H., et al. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01473-0 · Cited by 41
“Recent evidence links mTOR to drug resistance 23–25 .”
BackgroundA protracted war against cancer drug resistance
Tian, Y., Wang, X., Wu, C., Qiao, J., Jin, H. D., & Li, H. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03510-2 · Cited by 43
Franciosa, G., Smits, J. G. A., Minuzzo, S. A., Martínez‐Val, A., Indraccolo, S., & Olsen, J. V. (2021) · Nature Communications · doi:10.1038/s41467-021-22787-9 · Cited by 39
Drug-induced resistance evolution necessitates less aggressive treatment
Kuosmanen, T., Cairns, J., Noble, R., Beerenwinkel, N., Mononen, T., & Mustonen, V. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009418 · Cited by 38
“Recently, similar findings were reported also in cancer in the context of targeted cytostatic therapies [16, 17].”
Mutual regulation of TGFβ-induced oncogenic EMT, cell cycle progression and the DDR
Schuhwerk, H., & Brabletz, T. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.11.009 · Cited by 42
Temprine, K., Campbell, N. R., Huang, T. H., Langdon, E. M., Simon-Vermot, T., Mehta, K., Clapp, A., Chipman, M. E., & White, R. M. (2020) · Science Signaling · doi:10.1126/scisignal.aau1453 · Cited by 38
Multi-Omics Analysis of the Gut-Liver Axis Reveals the Mechanism of Liver Injury in Colitis Mice
Zhu, L., Zong, X., Xiao, X., Cheng, Y., Fu, J., Lu, Z., Jin, M., Wang, F., & Wang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.773070 · Cited by 42
“The downregulation of these two pathways often lead to cell damage, tumors, cancer and other diseases (70, 71).”
BackgroundDNA Damage Tolerance Pathways in Human Cells: A Potential Therapeutic Target
Ler, A. A. L., & Carty, M. P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.822500 · Cited by 42
Jia, L.-L., Zhao, J.-X., Zhao, L., Tian, J., & Huang, G. (2022) · European Journal of Radiology · doi:10.1016/j.ejrad.2022.110640 · Cited by 42
Sublethal engagement of apoptotic pathways in residual cancer
Killarney, S. T., Tait, S. W. G., Green, D. R., & Wood, K. C. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.07.005 · Cited by 42
Bacterial phenotypic heterogeneity in DNA repair and mutagenesis
Vincent, M. S., & Uphoff, S. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190364 · Cited by 39
Large-scale preparation of fluorescence multiplex host cell reactivation (FM-HCR) reporters
Piett, C. G., Pecen, T. J., Laverty, D. J., & Nagel, Z. D. (2021) · Nature Protocols · doi:10.1038/s41596-021-00577-3 · Cited by 39
Self-citationDrug-tolerant persister cells in cancer: bridging the gaps between bench and bedside
Wang, Z., Wang, M., Dong, B., Wang, Y., Ding, Z., & Shen, S. (2025) · Nature Communications · doi:10.1038/s41467-025-66376-6 · Cited by 61
“Since then, interest in DTP biology has grown rapidly, revealing a spectrum of adaptive traits, epigenetic reprogramming 6 , transcriptional memory 7 , translational remodelling 8 , metabolic shifts 9,10 and therapy-induced mutagenesis 11 , across diverse tumour types and treatments.”
HIF in Gastric Cancer: Regulation and Therapeutic Target
Li, M., Guan, L., Yang, X., Yin, W., Lv, G., & Wang, S. (2022) · Molecules · doi:10.3390/molecules27154893 · Cited by 36
Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer
Crupi, M. J. F., Taha, Z., Janssen, T. J. A., Petryk, J., Boulton, S., Alluqmani, N., Jirovec, A., Kassas, O., Khan, S., Vallati, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1029269 · Cited by 34
“For patients with metastatic CRC, the prognosis remains poor with 5-year survival rates below 20% due to the limited effectiveness of standard of care chemotherapy or targeted therapies (2).”
BackgroundGreco, L., Rubbino, F., Buono, A. D., & Laghi, L. (2023) · Genes · doi:10.3390/genes14061169 · Cited by 42
“On the other hand, basic science should continue to explore whether the therapeutic manipulation of CRC could be exploited to induce MSI [164], then allowing the employment of immunotherapy as an additional strategy for the therapy of CRC at large.”
BackgroundMutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer
Woolston, A., Barber, L. J., Griffiths, B. L., Pich, O., López-Bigas, N., Matthews, N., Rao, S., Watkins, D. J., Chau, I., Starling, N., et al. (2021) · Nature Ecology & Evolution · doi:10.1038/s41559-021-01470-8 · Cited by 34
“…21 ), b) additional signatures of mutational processes that were reported to increase through cetuximab-induced mutagenesis by Russo et al. 12 (HR ‐ deficiency signature SBS3, MMR ‐ deficiency signature SBS6 9,22 ) and c) the platinum chemotherapy signature SBS35 as all tumors had…”
InfluentialZhang, Z., Zheng, M., Ding, Q., & Liu, M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.817965 · Cited by 35
“As a vital factor associated with the stability and integrity of genome,MMRhas drawn considerable attention (Fishel, 2015; Russo et al., 2019).”
BackgroundZhu, H., Tian, Y., Chen, H., Qian, Y., Li, J., Niu, D., Zhao, W., Wu, Y., Zhang, X., Tang, T., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101287 · Cited by 34
CDK-independent role of D-type cyclins in regulating DNA mismatch repair
Róna, G., Miwatani-Minter, B., Zhang, Q., Goldberg, H. V., Kerzhnerman, M. A., Howard, J., Simoneschi, D., Lane, E., Hobbs, J. W., Sassani, E., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.02.010 · Cited by 35
Self-citationDevelopment of new techniques and clinical applications of liquid biopsy in lung cancer management
Chen, K., He, Y., Wang, W., Yuan, X., Carbone, D. P., & Yang, F. (2024) · 中国科学通报:英文版 · doi:10.1016/j.scib.2024.03.062 · Cited by 34
Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer
Delahaye, C., Figarol, S., Pradines, A., Favre, G., Mazières, J., & Calvayrac, O. (2022) · Cancers · doi:10.3390/cancers14112613 · Cited by 34
“A similar pseudo-dormant and reversible drug-tolerant phenotype have also been reported in other oncogenic contexts, such as glioblastoma [63,64], BRAF-mutant melanoma [65–67], colorectal cancers [59,68,69], breast cancers [70], or pancreatic cancer [71], treated either with targeted therapies or chemotherapies.”
BackgroundThe DNA Double-Strand Break Repair in Glioma: Molecular Players and Therapeutic Strategies
Maksoud, S. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02915-2 · Cited by 30
Cancer Cells Enter an Adaptive Persistence to Survive Radiotherapy and Repopulate Tumor
Zhao, Y., Lu, T., Song, Y., Wen, Y., Deng, Z., Fan, J., Zhao, M., Zhao, R., Luo, Y., xie, J., et al. (2023) · Advanced Science · doi:10.1002/advs.202204177 · Cited by 29
Marrocco, I., & Yarden, Y. (2023) · Cancers · doi:10.3390/cancers15205009 · Cited by 29
“It is worthwhile noting that in similarity to NSCLC cells, human CRC cells exploit adaptive mutability to evade the therapeutic pressure of a combined treatment that used a BRAF kinase inhibitor and an anti-EGFR antibody [129].”
BackgroundXu, J., Bian, X., Zhao, H., Sun, Y., Tian, Y., Li, X., & Tian, W. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07215-w · Cited by 29
Lallous, N., Snow, O., Sanchez, C., Nuñez, A. K. P., Sun, B., Hussain, A. B. S., Lee, J., Morin, H., Leblanc, E., Gleave, M. E., et al. (2021) · Cancers · doi:10.3390/cancers13122939 · Cited by 29
“However, a recent study [9] demonstrated that downregulation of DNA mismatch repair (MMR) and homologous recombination (HR) play a significant role in adaptive mutability in colorectal cancers, occurring as a response to therapeutic pressure.”
BackgroundClonal Architecture and Evolutionary Dynamics in Acute Myeloid Leukemias
Duchmann, M., Laplane, L., & Itzykson, R. (2021) · Cancers · doi:10.3390/cancers13194887 · Cited by 33
“Mutation rate can also transiently increase as an adaptive phenomenon in the context of therapeutic selection pressure [75].”
BackgroundTumor-promoting aftermath post-chemotherapy: A focus on breast cancer
Famta, P., Shah, S., Jain, N., Kumar, K. C., Bagasariya, D., Khatri, D. K., Raghuvanshi, R. S., Singh, S. B., & Srivastava, S. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121125 · Cited by 28
Cell-to-cell variability in Myc dynamics drives transcriptional heterogeneity in cancer cells
Liu, C., Kudo, T., Ye, X., & Gascoigne, K. E. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112401 · Cited by 30
Drugging evolution of antibiotic resistance at a regulatory network hub
Zhai, Y., Pribis, J. P., Dooling, S. W., García-Villada, L., Minnick, P. J., Xia, J., Liu, J., Mei, Q., Fitzgerald, D. M., Herman, C., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg0188 · Cited by 27
Caracciolo, D., Riillo, C., Arbitrio, M., Martino, M. T. D., Tagliaferri, P., & Tassone, P. (2020) · International Journal of Cancer · doi:10.1002/ijc.33038 · Cited by 32
“Recent evidence showed that resistance to EGFR inhibitor cetuximab in CRC cells is associated with downregulation of MMR and HR DNA repair genes.(55) As consequence, the authors show an upregulation of error-prone DNA polymerases, which facilitates bases mispairings, incorporation of aberrant DNA primer ends, and incr…”
BackgroundAn update on the use of immunotherapy in patients with colorectal cancer
Nguyen, M., Smith, S. T., Lam, M., Liow, E. C. H., Davies, A., Prenen, H., & Segelov, E. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1845141 · Cited by 31
“EGFR is implicated in the immune response, with preclinical data demonstrating a role in opsonization and phagocytosis of colonic cancer cells, T cell activation and natural killer (NK) cell activity [76] More recently, anti-EGFR therapy has been demonstrated to downregulate DNA repair mechanisms, which is correlated…”
BackgroundPan-Cancer Analysis of FURIN as a Potential Prognostic and Immunological Biomarker
Zhou, B., & Gao, S. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.648402 · Cited by 30
Ye, L.-F., Huang, Z.-Y., Chen, X., Chen, Z., Wu, S., Ren, C., Hu, M.-T., Bao, H., Jin, Y., Wang, F., et al. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100883 · Cited by 27
Targeting therapy-persistent residual disease
Sun, X., Wu, L. F., Altschuler, S. J., & Hata, A. N. (2024) · Nature Cancer · doi:10.1038/s43018-024-00819-9 · Cited by 29
“…a reasonable hypothesis is that even partial prevention will Perspective https://doi.org/10.1038/s43018-024-00819-9 and homologous recombination DNA repair genes while increasing error-prone polymerases in persister cells, resulting in elevated DNA damage, mutability and genomic instability 31 .”
InfluentialStrategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology
Gümüşay, Ö., Vitiello, P. P., Wabl, C. A., Corcoran, R. B., Bardelli, A., & Rugo, H. S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280845 · Cited by 33
Self-citationStimulation of adaptive gene amplification by origin firing under replication fork constraint
Whale, A. J., King, M. R., Hull, R. M., Krueger, F., & Houseley, J. M. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1257 · Cited by 27
“However, neither does this constitute a stress-induced mutational pathway equivalent to the bacterial SOS response or recent reports of adaptive mutability during chemotherapy (103-105).”
BackgroundCancer organoid applications to investigate chemotherapy resistance
Harada, K., & Sakamoto, N. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1067207 · Cited by 26
“drug resistance after a long latency period (Ramirez et al., 2016; Russo et al., 2019).”
BackgroundRecent advances of pathomics in colorectal cancer diagnosis and prognosis
Wu, Y., Li, Y., Xiong, X., Liu, X., Lin, B., & Xu, B. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1094869 · Cited by 34
Colorectal cancer spectrum: From subtypes and epidemiology to oncotherapies
Agrawal, N., Lanjhiyana, S. K., Jaiswal, M., Siddiqui, M. A., & Gupta, S. (2025) · Gastroenterology & Endoscopy · doi:10.1016/j.gande.2025.01.002 · Cited by 29
Zhou, M., Niu, H., Cui, D., Xu, M., Li, J., Huang, G., Zhou, M., Xiong, C., Liu, Y., Xu, X., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02557-7 · Cited by 33
“Prolonged chemotherapy exposure drives genetic mutations, which are a key mechanism of tumor drug resistance [34, 77–80].”
InfluentialTomasini, P. P., Guecheva, T. N., Leguisamo, N. M., Péricart, S., Brunac, A., Hoffmann, J., & Saffi, J. (2021) · Cancers · doi:10.3390/cancers13133130 · Cited by 26
“This observation may reveal another opportunity to elucidate whether anti-VEGF/EGFR-resistant CRC cells may be sensitized by agents, such as PARP inhibitors or the novel agents targeting the ATR-CHK1-WEE1 axis [269].”
BackgroundMolecular testing for colorectal cancer: Clinical applications
Имянитов, Е. Н., & Kuligina, E. S. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i10.1288 · Cited by 32
Randon, G., Intini, R., Cremolini, C., Elez, E., Overman, M. J., Lee, J., Manca, P., Bergamo, F., Pagani, F., Antista, M., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.018 · Cited by 24
Targeting Replication Stress Response Pathways to Enhance Genotoxic Chemo- and Radiotherapy
Nickoloff, J. A. (2022) · Molecules · doi:10.3390/molecules27154736 · Cited by 33
Blockade of the amino acid transporter SLC6A14 suppresses tumor growth in colorectal Cancer
Lü, Y., Jiang, Z., Wang, K., Yu, S., Hao, C., Ma, Z., Fu, X., Qin, M., Xu, Z., & Fan, L. (2022) · BMC Cancer · doi:10.1186/s12885-022-09935-0 · Cited by 31
“Nowadays, gene microarrays, protein microarrays, and tumor metabonomics are all important means for identification of tumor markers, serodiagnosis, and new targeted therapies [4, 5].”
BackgroundPersister cell plasticity in tumour drug resistance
McDonald, P. C., & Dedhar, S. (2023) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2023.11.003 · Cited by 32
Reverting to single-cell biology: The predictions of the atavism theory of cancer
Bussey, K. J., & Davies, P. C. W. (2021) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2021.08.002 · Cited by 32
“They found that mismatch repair and homologous double-strand break repair pathways were down regulated, while translesion synthesis polymerase was concomitantly up-regulated in cells that acquire permanent resistance to therapy (Russo et al., 2019).”
BackgroundHeterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes
Gaiani, F., Marchesi, F., Negri, F., Greco, L., Malesci, A., de’Angelis, G. L., & Laghi, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105246 · Cited by 30
Berger, A. J., Gigi, E., Kupershmidt, L., Meir, Z., Gavert, N. S., Zwang, Y., Pri-Or, A., Gilad, S., Harush, U., Haviv, I., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00261-1 · Cited by 25
Hoffman, T. E., Nangia, V., Ill, C. R., Passanisi, V. J., Armstrong, C., Yang, C., & Spencer, S. L. (2023) · Science Signaling · doi:10.1126/scisignal.ade8744 · Cited by 22
“Whereas unperturbed cycling cells typically display a low basal level of γ-H2AX staining (29, 32, 41, 45, 50), we found that this level was increased further in cells cycling amid MAPK inhibition (Fig.”
BackgroundColorectal cancer with BRAF V600E mutation: Trends in immune checkpoint inhibitor treatment
Liu, M., Liu, Q., Hu, K., Dong, Y., Sun, X., Zou, Z., Ji, D., Liu, T., & Yu, Y. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104497 · Cited by 25
El Meouche, I., Jain, P., Jolly, M. K., & Capp, J.-P. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102069 · Cited by 22
“Also, the DNA repair is compromised in persister cells from colorectal cancers and resulted in elevated DNA damage, most likely caused by the formation of ROS as a source of DNA damage[118].”
BackgroundShapiro, J. A. (2021) · Cancers · doi:10.3390/cancers13061358 · Cited by 23
“Can we find evidence for the operation of such NGE systems in cancers and recognize patterns that may lead to possible therapeutic interventions? Heng and colleagues have characterized the rapid genome restructuring episodes leading to tumor cells with novel adaptive capabilities [9] as “Genome Chaos” [1,10].”
BackgroundLiu, C., Papukashvili, D., Dong, Y., Wang, X., Hu, X., Yang, N., Cai, J., Xie, F., Rcheulishvili, N., & Wang, P. G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.783527 · Cited by 28
“Especially late-stage CRC patients still have a relatively poor prognosis (Hammond et al., 2016; Russo et al., 2019).”
BackgroundNew developments in targeted therapy for metastatic colorectal cancer
Wong, A. H. N., Ma, B. B. Y., & Lui, R. N.-S. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221148540 · Cited by 24
Mendez‐Dorantes, C., Tsai, L. J., Jahanshir, E., Lopezcolorado, F. W., & Stark, J. M. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.001 · Cited by 21
“, 1993) and such tumors that downregulate mismatch repair in response to therapy (Russo et al., 2019).”
BackgroundTransforming cancer cells for long-term living with cancer: An inspiring new approach
Jiang, M., Gu, D.-N., Liu, F.-R., Lin, C.-J., & Tian, L. (2023) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2023.02.03 · Cited by 22
Wu, Y., Zhong, D., Li, Y., Wu, H., Zhang, H., Mao, H., Yang, J., Luo, K., Gong, Q., & Gu, Z. (2021) · Nanoscale · doi:10.1039/d0nr08487e · Cited by 21
Jayappa, K. D., Gordon, V. L., Morris, C. G., Wilson, B., Shetty, B. D., Cios, K. J., Arora, P. C., Isaac, K. M., Saha, S., Bender, T. P., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003944 · Cited by 22
“Further, as recently suggested, cancer cells that accumulate DNA damage but fail to activate cell death are a potential source for development of drug-resistant mutants.(81) Consistent with this hypothesis, some patients with CLL develop resistance to venetoclax while on treatment by acquiring mutations at the drug-bi…”
BackgroundSun, H., Liu, C., Han, F., Lin, X., Cao, L., Liu, C., Ji, Q., Cui, J., Yao, Y., Wang, B., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01118-z · Cited by 24
Toomey, S., Gunther, J. R., Carr, A., Weksberg, D. C., Thomas, V., Salvucci, M., Bacon, O., Sherif, E.-M., Fay, J., Kay, E. W., et al. (2020) · Cancers · doi:10.3390/cancers12071808 · Cited by 21
“Recent research has suggested a role for adaptive mutability to targeted therapy in colorectal cancer cells [32].”
BackgroundThe many faces of cancer evolution
Ciriello, G., & Magnani, L. (2021) · iScience · doi:10.1016/j.isci.2021.102403 · Cited by 22
Immune Infiltration of MMP14 in Pan Cancer and Its Prognostic Effect on Tumors
Li, M., Li, S., Zhou, L., Yang, L., Wu, X. Q., Tang, B., Xie, S., Fang, L., Zheng, S., & Hong, T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.717606 · Cited by 24
“This potentially defective biomarker caused by the deletion of the MMP gene is called MSI (66).”
BackgroundSenescence-associated reprogramming induced by interleukin-1 impairs response to EGFR neutralization
Romaniello, D., Gelfo, V., Pagano, F., Ferlizza, E., Sgarzi, M., Mazzeschi, M., Morselli, A., Miano, C., D’Uva, G., & Lauriola, M. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00319-7 · Cited by 21
“Epidermal growth factor receptor (EGFR)/BRAF inhibition by CTX represses several DNA repair genes with consequent induction of DNA damage [30] and cellular senescence [31].”
BackgroundRe-Sensitizing Cancer Stem Cells to Conventional Chemotherapy Agents
Kim, M., Bakyt, L., Akhmetkaliyev, A., Toktarkhanova, D., & Bulanin, D. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032122 · Cited by 22
Homopolymer switches mediate adaptive mutability in mismatch repair-deficient colorectal cancer
Kayhanian, H., Cross, W. C. H., van der Horst, S. E. M., Barmpoutis, P., Lakatos, E., Caravagna, G., Zapata, L., van Hoeck, A., Middelkamp, S., Litchfield, K., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01777-9 · Cited by 22
“This confirmed that the largest chunk of the tumor genome is in a heterozygous diploid state, with a single copy of the major and minor alleles, which is expected from CRCs with MSI 39 .”
InfluentialNeoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma
Chen, P., Fang, Q., Chen, D., & Chen, H. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i7.673 · Cited by 22
Deep profiling of gene expression across 18 human cancers
Qiu, W., Dincer, A. B., Janizek, J. D., Çelik, S., Pittet, M. J., Naxerova, K., & Lee, S. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01290-8 · Cited by 27
“Similarly, reduced expression of mismatch repair proteins can increase mutability and microsatellite instability 70 .”
Serratì, S., Porcelli, L., Fragassi, F., Garofoli, M., Fonte, R., Fucci, L., Iacobazzi, R. M., Palazzo, A., Margheri, F., Cristiani, G., et al. (2021) · Cancers · doi:10.3390/cancers13102505 · Cited by 19
Li, M., Zhang, R., Xin, M., Xu, Y., Liu, S., Yu, B., Zhang, B., & Liu, J. (2022) · Metabolites · doi:10.3390/metabo12100997 · Cited by 18
Characteristics and molecular mechanism of drug-tolerant cells in cancer: a review
Liang, X.-W., Liu, B., Chen, J.-C., Cao, Z. W., Chu, F.-R., Xiong, L., Wang, S.-Z., & Wu, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1177466 · Cited by 20
“Moreover, DNA damage repair genes are down-regulated in tumour cells as they acquire drug resistance, leading to more DNA damage (56, 57).”
BackgroundChen, C. T., Bartolomeo, M. D., Corallo, S., Strickler, J. H., & Goyal, L. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280871 · Cited by 20
Fu, Y., Yang, B., Cui, Y., Hu, X., Li, X., Lu, F., Qin, T., Zhang, L., Hu, Z., Guo, E., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006070 · Cited by 24
“…several strategies, such as inactivating MLH1 through genome editing technology 9 or BRAF or EGFR inhibitors in BRAF-mutated colorectal cancer 10 can convert tumors from MMR-proficient (pMMR) to dMMR status with the hope of improving tumor response to ICB by inducing genetic instability and…”
A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib
Nieves, A. S., Lindzen, M., Giri, S., Gupta, N., Chatterjee, R., Selvadurai, B.-R., Daele, M. V., Love, D., Haga, Y., Romaniello, D., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101703 · Cited by 28
“27,51 Specifically, following treatment with a TKI, such as osimertinib, both MMR and HR repair genes undergo down-regulation, as do several high-fidelity DNA polymerases.”
Early tolerance and late persistence as alternative drug responses in cancer
Punzi, S., Cittaro, D., Gatti, G., Crupi, G., Botrugno, O. A., Cartalemi, A. A., Gutfreund, A., Oneto, C., Giansanti, V., Battistini, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-54728-7 · Cited by 24
Self-citationYeoh, Y., Low, T. Y., Abu, N., & Lee, P. Y. (2021) · PeerJ · doi:10.7717/peerj.12338 · Cited by 19
Zhao, P., Jiao, Y.-N., Ma, Z.-F., Yang, Y., Li, Y., Hu, S.-D., Li, S.-Y., & Du, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.947658 · Cited by 17
Wang, Y., Chen, P., Zhao, M., Cao, H., Zhao, Y., Ji, M., Hou, P., & Chen, M. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05354-y · Cited by 18
“Although onset of new mutants or histology demonstrated in clinical samples [5] seems to support that primary resistance plays a major role, those data can also be explained by either parallel evolution [6] or adaptive mutability caused by inhibition of EGFR [7].”
BackgroundMarrocco, I., Giri, S., Nieves, A. S., Gupta, N., Rudnitsky, A., Haga, Y., Romaniello, D., Sekar, A., Zerbib, M., Oren, R., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101142 · Cited by 22
“Analogously, it has been reported that a combination of cetuximab and a kinase inhibitor downregulated several MMR genes.(40) Taken together, the results presented in Figure 7 propose that cetuximab might prevent tumor relapses due to its ability to inhibit the AXL-to-RAD18/ PCNA mutagenic pathway.”
BackgroundResultTargeted drugs ramp up cancer mutability
Gerlinger, M. (2019) · Science · doi:10.1126/science.aaz9900 · Cited by 18
Feng, L., Li, M., Hu, X., Li, Y., Zhu, L., Chen, M., Wei, Q., Xu, W., Zhou, Q., Wang, W., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.587 · Cited by 18
Shimizu, Y., Okada, K., Adachi, J., Abe, Y., Narumi, R., Uchibori, K., Yanagitani, N., Koike, S., Takagi, S., Nishio, M., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00260-0 · Cited by 18
Antigen-capturing oncolytic adenoviruses along with IDO blockade for improved tumor immunotherapy
Chen, X., Cheng, K., Wang, X., Liu, J., Liang, J., Liu, G., Lu, Y., Tang, M., Qian, D., Chen, L., et al. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101922 · Cited by 16
Li, F., Guo, E., Huang, J. M., Lu, F., Yang, B., Xiao, R., Liu, C., Wu, X. Y., Fu, Y., Wang, Z., et al. (2020) · American Journal of Cancer Research · Cited by 25
Metadata
- Authors
- Russo, M., Crisafulli, G., Sogari, A., Reilly, N. M., Arena, S., Lamba, S., Bartolini, A., Amodio, V., Magrì, A., Novara, L., Sarotto, I., Nagel, Z. D., Piett, C. G., Amatu, A., Sartore-Bianchi, A., Siena, S., Bertotti, A., Trusolino, L., Corigliano, M., Gherardi, M., Lagomarsino, M. C., Di Nicolantonio, F., & Bardelli, A.
- Affiliations
- Candiolo Cancer Institute (IT)
- Fondazione Piemontese per la Ricerca sul Cancro Onlus (IT)
- Harvard University (US)
- University of Milan (IT)
- Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy.
- Candiolo Cancer Institute, FPO–IRCCS, Candiolo (TO) 10060, Italy.
- Corresponding author
- Russo, Mariangela
- Bardelli, Alberto
- ORCID
- Russo, Mariangela
- Crisafulli, Giovanni
- Sogari, Alberto
- Reilly, Nicole M.
- Arena, Sabrina
- Lamba, Simona
- Bartolini, Alice
- Amodio, Vito
- Magrì, Alessandro
- Novara, Luca
- Sarotto, Ivana
- Nagel, Zachary D.
- Piett, Cortt G.
- Amatu, Alessio
- Sartore-Bianchi, Andrea
- Siena, Salvatore
- Bertotti, Andrea
- Trusolino, Livio
- Corigliano, Mattia
- Gherardi, Marco
- Lagomarsino, Marco Cosentino
- Di Nicolantonio, Federica
- Bardelli, Alberto
- Venue
- Science
- Published
- 2019-12-20
- Volume
- 366
- Issue
- 6472
- Pages
- 1473-1480
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2987148655
- Cited by
- 433
- References
- 62
- Citations by year
- 2026: 41 · 2025: 55 · 2024: 60 · 2023: 70 · 2022: 76 · 2021: 72 · 2020: 57 · 2019: 2
- FWCI
- 21.60
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- H2020 Health (635342-2 MoTriColor, no. 754923 COLOSSUS)
- Ministero della Salute (Ricerca Corrente 2019 RC2019)
- Associazione Italiana per la Ricerca sul Cancro (9970 Extension program, IG. 16788, ID. 21091, ID.21091, AIRC IG 2018 - ID. 21923)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- colorectal cancer, drug resistance, targeted therapy, EGFR inhibition, BRAF inhibition, DNA mismatch repair, homologous recombination, error-prone DNA polymerases, microsatellite instability, drug-tolerant persister cells, DNA damage, patient-derived xenografts
- MeSH terms
- Adaptation, Biological, Humans, Selection, Genetic, Colorectal Neoplasms, Down-Regulation, Mutagenesis, Drug Resistance, Neoplasm, Proto-Oncogene Proteins B-raf, DNA Mismatch Repair, Molecular Targeted Therapy, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.